Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Clopidogrel
Accession Number
DB00758  (APRD00444)
Type
Small Molecule
Groups
Approved
Description

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.3,9 Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,9

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.8

Clopidogrel was granted FDA approval on 17 November 1997.9

Structure
Thumb
Synonyms
  • (+)-Clopidogrel
  • Clopidogrel
  • Clopidogrelum
External IDs
R 130964 / R-130964 / SR 25990 / SR-25990
Product Ingredients
IngredientUNIICASInChI Key
Clopidogrel besilateBL9VGG8BHW744256-69-7CUZIJKLLBDXNFV-RSAXXLAASA-N
Clopidogrel bisulfate08I79HTP27120202-66-6FDEODCTUSIWGLK-RSAXXLAASA-N
Clopidogrel hydrochloride426O7XWS6Y120202-65-5XIHVAFJSGWDBGA-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act ClopidogrelTabletOralActavis Pharma Company2011-12-07Not applicableCanada
ClopidogrelTablet75 mgOralSanis Health Inc2013-02-13Not applicableCanada
ClopidogrelTablet75 mgOralPro Doc Limitee2012-11-22Not applicableCanada
ClopidogrelTablet75 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-162010-01-26Eu
Clopidogrel BmsTablet, film coated300 mgOralBristol Myers Squibb Pharma Eeig2008-07-162010-01-26Eu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-162010-01-26Eu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-162010-01-26Eu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-162010-01-26Eu
Clopidogrel BmsTablet, film coated75 mgOralBristol Myers Squibb Pharma Eeig2008-07-162010-01-26Eu
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-clopidogrelTabletOralAbbott2014-03-172015-12-31Canada
Accel-clopidogrelTabletOralAccel Pharma IncNot applicableNot applicableCanada
Accel-clopidogrelTabletOralAccel Pharma Inc2014-09-042015-11-09Canada
Ag-clopidogrelTabletOralAngita Pharma Inc.Not applicableNot applicableCanada
Apo-clopidogrelTabletOralApotex Corporation2013-01-21Not applicableCanada
Apo-clopidogrelTabletOralApotex Corporation2011-12-19Not applicableCanada
Auro-clopidogrelTabletOralAuro Pharma Inc2014-02-06Not applicableCanada
Bio-clopidogrelTabletOralBiomed Pharma2019-09-23Not applicableCanada
Clopido Grel 1a PharmaTablet, film coated75 mgOralAcino Pharma Gmb H2009-07-282013-01-18Eu
Clopidogre RatiopharmTablet, film coated75 mgOralTeva B.V.2015-02-19Not applicableEu
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Clopidogrel KitClopidogrel bisulfate (75 mg/1) + Acetylsalicylic acid (81 mg/1)KitOralCambridge Therapeutics Technologies, Llc2017-07-01Not applicableUs
DuoplavinClopidogrel (75 mg) + Acetylsalicylic acid (75 mg)Tablet, film coatedOralSanofi Pharma Bristol Myers Squibb Snc2010-03-15Not applicableEu
DuoplavinClopidogrel (75 mg) + Acetylsalicylic acid (100 mg)Tablet, film coatedOralSanofi Pharma Bristol Myers Squibb Snc2010-03-15Not applicableEu
DuoplavinClopidogrel (75 mg) + Acetylsalicylic acid (75 mg)Tablet, film coatedOralSanofi Pharma Bristol Myers Squibb Snc2010-03-15Not applicableEu
DuoplavinClopidogrel (75 mg) + Acetylsalicylic acid (75 mg)Tablet, film coatedOralSanofi Pharma Bristol Myers Squibb Snc2010-03-15Not applicableEu
DuoplavinClopidogrel (75 mg) + Acetylsalicylic acid (100 mg)Tablet, film coatedOralSanofi Pharma Bristol Myers Squibb Snc2010-03-15Not applicableEu
DuoplavinClopidogrel (75 mg) + Acetylsalicylic acid (75 mg)Tablet, film coatedOralSanofi Pharma Bristol Myers Squibb Snc2010-03-15Not applicableEu
DuoplavinClopidogrel (75 mg) + Acetylsalicylic acid (75 mg)Tablet, film coatedOralSanofi Pharma Bristol Myers Squibb Snc2010-03-15Not applicableEu
DuoplavinClopidogrel (75 mg) + Acetylsalicylic acid (100 mg)Tablet, film coatedOralSanofi Pharma Bristol Myers Squibb Snc2010-03-15Not applicableEu
DuoplavinClopidogrel (75 mg) + Acetylsalicylic acid (75 mg)Tablet, film coatedOralSanofi Pharma Bristol Myers Squibb Snc2010-03-15Not applicableEu
Categories
UNII
A74586SNO7
CAS number
113665-84-2
Weight
Average: 321.822
Monoisotopic: 321.059027158
Chemical Formula
C16H16ClNO2S
InChI Key
GKTWGGQPFAXNFI-HNNXBMFYSA-N
InChI
InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
IUPAC Name
methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate
SMILES
[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl

Pharmacology

Indication

Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,9

Associated Conditions
Pharmacodynamics

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.3,9 It has a long duration of action as it is taken once daily and a large therapeutic window as it is given in doses of 75-300mg daily.9

Mechanism of action

Clopidogrel is metabolized to its active form by carboxylesterase-1.3 The active form is a platelet inhibitor that irreversibly binds to P2Y12 ADP receptors on platelets.9 This binding prevents ADP binding to P2Y12 receptors, activation of the glycoprotein GPIIb/IIIa complex, and platelet aggregation.9

TargetActionsOrganism
AP2Y purinoceptor 12
antagonist
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

A 75mg oral dose of clopidogrel is 50% absorbed from the intestine.9 Clopidogrel can be taken with or without food.9 A meal decreases the AUC of the active metabolite by 57%.9 The active metabolite of clopidogrel reaches a maximum concentration after 30-60 minutes.9 Clopidogrel reached a Cmax of 2.04±2.0ng/mL in 1.40±1.07h.5

The AUC for a 300mg oral dose of clopidogrel was 45.1±16.2ng*h/mL for poor metabolizers, 65.6±19.1ng*h/mL for intermediate metabolizers, and 104.3±57.3ng*h/mL for extensive metabolizers.6 The Cmax was 31.3±13ng/mL for poor metabolizers, 43.9±14ng/mL for intermediate metabolizers, and 60.8±34.3ng/mL for extensive metabolizers.6

Volume of distribution

The apparent volume of distribution of clopidogrel is 39,240±33,520L.5

Protein binding

Both the active and inactive metabolites of clopidogrel are 98% protein bound in plasma.1 Studies in cows show clopidogrel 71-85.5% bound to serum albumin.2

Metabolism

85-90% of an oral dose undergoes first pass metabolism by carboxylesterase 1 in the liver to an inactive carboxylic acid metabolite.4 about 2% of clopidogrel is oxidized to 2-oxoclopidogrel.4 This conversion is 35.8% by CYP1A2, 19.4% by CYP2B6, and 44.9% by CYP2C194 though other studies suggest CYP3A4, CYP3A5, and CYP2C9 also contribute.3 2-oxoclopidogrel is further metabolized to the active metabolite.3,4 This conversion is 32.9% by CYP2B6, 6.79% by CYP2C9, 20.6% by CYP2C19, and 39.8% by CYP3A4.3,4

Route of elimination

An oral dose of radiolabelled clopidogrel is excreted 50% in the urine and 46% in the feces over 5 days.9 The remainder of clopidogrel is irreversibly bound to platelets for their lifetime, or approximately 8-11 days.7

Half life

That half life of clopidogrel is approximately 6 hours following a 75mg oral dose while the half life of the active metabolite is approximately 30 minutes.9

Clearance

The clearance of a 75mg oral dose was 18,960±15,890L/h and for a 300mg oral dose was 16,980±10,410L/h.5

Toxicity

A single dose of clopidogrel at 1500-2000mg/kg was lethal to mice and rats while 3000mg/kg was lethal to baboons.9 Symptoms of overdose include vomiting, breathing difficulty, gastrointestinal hemorrhage, and prostration.9 Clopidogrel is irreversibly bound to platelets for their lifetime, which is approximately 11 days.9 Overdoses of clopidogrel can be treated with platelet transfusions to restore clotting ability.9

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Clopidogrel Action PathwayDrug action
Clopidogrel Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*3(C;C) / (A;C)C AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of clopidogrel resulting in reduced plasma concentrations of its active metabolite.Details
Cytochrome P450 2C19CYP2C19*2(A;A) / (A;G)G > AEffect Directly StudiedPatients with this genotype have reduced metabolism of clopidogrel resulting in reduced plasma concentrations of its active metabolite.Details
Cytochrome P450 2C19CYP2C19*2Not Available681G>AADR Directly StudiedPatients with this polymorphism in CYP2C19 are poor metabolizers of clopidogrel and are associated with diminished platelet response and increased risk of adverse cardiovascular events in response to clopidogrel therapy.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>ADirectly Studied EffectThe presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of clopidogrel.Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AADR InferredPoor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AADR InferredPoor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GADR InferredPoor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TADR InferredPoor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AADR InferredPoor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AADR InferredPoor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GADR InferredPoor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all ADR InferredPoor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GADR InferredPoor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*2Not Available430C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactionsDetails

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Clopidogrel is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Clopidogrel is combined with (S)-Warfarin.
25-desacetylrifapentineThe therapeutic efficacy of Clopidogrel can be increased when used in combination with 25-desacetylrifapentine.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Clopidogrel is combined with 4-hydroxycoumarin.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Clopidogrel.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Clopidogrel.
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Clopidogrel.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Clopidogrel.
9-DeazaguanineThe metabolism of 9-Deazaguanine can be decreased when combined with Clopidogrel.
9-MethylguanineThe metabolism of 9-Methylguanine can be decreased when combined with Clopidogrel.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

Synthesis Reference

Revital Lifshitz-Liron, "Novel crystal forms III, IV, V, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form I, compositions containing the new forms and methods of administering the new forms." U.S. Patent US20030114479, issued June 19, 2003.

US20030114479
General References
  1. Ganesan S, Williams C, Maslen CL, Cherala G: Clopidogrel variability: role of plasma protein binding alterations. Br J Clin Pharmacol. 2013 Jun;75(6):1468-77. doi: 10.1111/bcp.12017. [PubMed:23116430]
  2. Mostafizar M, Haque P, Mazid A, Shohel M, Shazly G, Kazi M, Reza HM: CHARACTERIZATION OF BINDING SITES OF CLOPIDOGREL AND INTERFERENCE OF LINOLEIC ACID AT THE BINDING SITE ON BOVINE SERUM ALBUMIN. Acta Pol Pharm. 2017 Jan;74(1):119-125. [PubMed:29474768]
  3. Zhang YJ, Li MP, Tang J, Chen XP: Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. Int J Environ Res Public Health. 2017 Mar 14;14(3). pii: ijerph14030301. doi: 10.3390/ijerph14030301. [PubMed:28335443]
  4. Jiang XL, Samant S, Lesko LJ, Schmidt S: Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147-66. doi: 10.1007/s40262-014-0230-6. [PubMed:25559342]
  5. Karazniewicz-Lada M, Danielak D, Burchardt P, Kruszyna L, Komosa A, Lesiak M, Glowka F: Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet. 2014 Feb;53(2):155-64. doi: 10.1007/s40262-013-0105-2. [PubMed:24127209]
  6. Umemura K, Iwaki T: The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers. Clin Pharmacol Drug Dev. 2016 Nov;5(6):480-487. doi: 10.1002/cpdd.259. Epub 2016 Apr 25. [PubMed:27514617]
  7. Frelinger AL 3rd, Barnard MR, Fox ML, Michelson AD: The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv. 2010 Oct;3(5):442-9. doi: 10.1161/CIRCINTERVENTIONS.110.937961. Epub 2010 Aug 24. [PubMed:20736449]
  8. Plosker GL, Lyseng-Williamson KA: Clopidogrel: a review of its use in the prevention of thrombosis. Drugs. 2007;67(4):613-46. doi: 10.2165/00003495-200767040-00013. [PubMed:17352522]
  9. FDA Approved Drug Products: Clopidogrel Tablets [Link]
External Links
Human Metabolome Database
HMDB0005011
KEGG Drug
D00769
PubChem Compound
60606
PubChem Substance
46507295
ChemSpider
54632
BindingDB
50318910
ChEBI
37941
ChEMBL
CHEMBL1771
Therapeutic Targets Database
DAP000178
PharmGKB
PA449053
HET
CGE
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Clopidogrel
ATC Codes
B01AC04 — Clopidogrel
AHFS Codes
  • 20:12.18 — Platelet Aggregation Inhibitors
PDB Entries
3me6 / 4h1n
FDA label
Download (402 KB)
MSDS
Download (57.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceAortic Valve Stenosis / Inflammatory Reaction / Thrombotic events1
0CompletedTreatmentPeripheral Vascular Disease Patient1
0RecruitingTreatmentStroke, Ischemic1
1Active Not RecruitingOtherCardiovascular Heart Disease / Elevated Lipoprotein(a)1
1Active Not RecruitingTreatmentHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers9
1CompletedNot AvailableHealthy Volunteers / Pharmacodynamic Interaction1
1CompletedNot AvailablePharmacodynamics1
1CompletedNot AvailableThrombotic events1
1CompletedBasic ScienceBioequivalence, AUC, Cmax, Pharmacokinetics1
1CompletedBasic ScienceCYP2C19 Genotypes1
1CompletedBasic ScienceCardiovascular Heart Disease1
1CompletedBasic ScienceCoronary Artery Disease1
1CompletedBasic ScienceDrug Drug Interaction (DDI)1
1CompletedBasic ScienceHealthy Volunteers9
1CompletedBasic ScienceInhibition on Platelet Aggregation1
1CompletedOtherHealthy Volunteers2
1CompletedTreatmentAcute Coronary Syndromes (ACS)2
1CompletedTreatmentAntiplatelet Effect1
1CompletedTreatmentAtherosclerosis1
1CompletedTreatmentChronic Kidney Disease (CKD)1
1CompletedTreatmentCoronary Artery Disease4
1CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Mixed hypercholesterolemia1
1CompletedTreatmentFasting2
1CompletedTreatmentFocus of Study / Pharmacokinetics and Pharmacodynamics in Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers12
1CompletedTreatmentHealthy Volunteers / Hemostasis1
1CompletedTreatmentHealthy Volunteers / PK/PD1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentPlatelet Aggregation1
1Not Yet RecruitingTreatmentCarotid Stenosis1
1RecruitingTreatmentAorta-iliac Segment Lesion (C,D Type by TASC II)1
1RecruitingTreatmentCoronary Artery Disease1
1RecruitingTreatmentHead and Neck Carcinoma1
1RecruitingTreatmentHealthy Volunteers1
1TerminatedHealth Services ResearchComparative Bioavailability of Clopidogrel Tablets1
1TerminatedPreventionHuman Immunodeficiency Virus (HIV)1
1TerminatedScreeningAcute Coronary Syndromes (ACS)2
1TerminatedTreatmentAcute Coronary Syndromes (ACS)1
1TerminatedTreatmentHealthy Volunteers / Hemostasis1
1Unknown StatusTreatmentCoronary Artery Disease1
1WithdrawnPreventionAspirin / Clopidogrel / Stroke / Transient Ischaemic Attack (TIA)1
1, 2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1, 2RecruitingTreatmentBleeding / Hemorrhage / Platelet Dysfunction Due to Drugs / Platelets Dysfunction1
2CompletedBasic ScienceCoronary Artery Disease1
2CompletedBasic ScienceInhibition of Platelet Aggregation in Response to Clopidogrel May be Accentuated by Trimetazidine / Platelet Dysfunction Due to Drugs1
2CompletedDiagnosticClopidogrel1
2CompletedDiagnosticDiabetes / Retinopathy, Diabetic1
2CompletedDiagnosticDisease Susceptibility1
2CompletedPreventionAtherosclerosis1
2CompletedPreventionCardiovascular Heart Disease / Human Immunodeficiency Virus (HIV) / Inflammatory Reaction1
2CompletedPreventionCritical Limb Ischemia (CLI)1
2CompletedPreventionPeptic Ulcer1
2CompletedScreeningAcute Coronary Syndromes (ACS) / Coronary Artery Disease / Heart Diseases / Myocardial Infarction / Stent Thrombosis1
2CompletedTreatmentAcute Coronary Syndromes (ACS)5
2CompletedTreatmentAcute Coronary Syndromes (ACS) / Coronary Arteriosclerosis1
2CompletedTreatmentAcute Coronary Syndromes (ACS) / Stable Angina (SA) / Unstable Angina Pectoris1
2CompletedTreatmentAtherosclerosis / Myocardial Infarction / Myocardial Ischemia1
2CompletedTreatmentBlood Platelet Disorders / Defect, Congenital Heart1
2CompletedTreatmentCardiovascular Heart Disease / Heart Diseases1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Coronary Artery Disease1
2CompletedTreatmentCoronary Artery Disease2
2CompletedTreatmentCoronary Artery Disease / Diabetes Mellitus1
2CompletedTreatmentCoronary Artery Disease / Percutaneous Coronary Intervention / Platelet Aggregation Inhibitors1
2CompletedTreatmentHead and Neck Carcinoma / Thromboembolism1
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1) Infection1
2CompletedTreatmentIntermittent Claudication1
2CompletedTreatmentIschaemia1
2CompletedTreatmentMyocardial Infarction / Percutaneous Coronary Intervention1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentPercutaneous Coronary Intervention1
2CompletedTreatmentPeripheral Arterial Disease (PAD)1
2CompletedTreatmentPulmonary Hypertension (PH)1
2CompletedTreatmentStable Angina (SA)1
2CompletedTreatmentStable Coronary Artery Disease2
2RecruitingPreventionAcute Ischemic Stroke (AIS) / Transient Ischaemic Attack (TIA)1
2RecruitingTreatmentAbnormal Renal Function / Adenosine / Antiplatelet Therapy / Coronary Artery Disease / Platelet Aggregation1
2RecruitingTreatmentAtrial Fibrillation (AF) / Cerebral Hemorrhage1
2RecruitingTreatmentCarotid Artery Stenosis1
2RecruitingTreatmentCritical Illness1
2TerminatedTreatmentCoronary Artery Disease1
2Unknown StatusBasic ScienceAsthma1
2Unknown StatusTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
2WithdrawnTreatmentPolycythemia Vera (PV)1
2, 3Active Not RecruitingTreatmentStroke / Transient Ischaemic Attack (TIA)1
2, 3CompletedDiagnosticPlatelet Reactivity1
2, 3CompletedPreventionStroke / Transient Ischaemic Attack (TIA)1
2, 3CompletedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
2, 3CompletedTreatmentAcute Coronary Syndromes (ACS) / Percutaneous Coronary Intervention1
2, 3CompletedTreatmentCoronary Artery Disease1
2, 3CompletedTreatmentCoronary Heart Disease (CHD)1
2, 3CompletedTreatmentMyocardial Infarction1
2, 3CompletedTreatmentMyocardial Infarction / Stroke1
2, 3CompletedTreatmentPeripheral Vascular Disease Patient1
2, 3RecruitingPreventionCoronary Artery Disease1
2, 3RecruitingTreatmentClopidogrel, Poor Metabolism of / Coronary Artery Disease1
2, 3RecruitingTreatmentPeripheral Arterial Disease (PAD)1
2, 3RecruitingTreatmentRecurrent Pregnancy Losses1
2, 3TerminatedTreatmentStroke, Ischemic / Transient Ischaemic Attack (TIA)1
2, 3Unknown StatusTreatmentCLOPIDOGREL, POOR METABOLISM of (Disorder)1
2, 3Unknown StatusTreatmentCoronary Artery Disease1
2, 3Unknown StatusTreatmentStroke, Ischemic / Transient Ischaemic Attack (TIA)1
3Active Not RecruitingPreventionStroke / Transient Ischaemic Attack (TIA)1
3Active Not RecruitingTreatmentPeripheral Arterial Disease (PAD)1
3CompletedNot AvailableIschemic Heart Disease1
3CompletedDiagnosticAortic Valve Stenosis / Cardiovascular Heart Disease / Heart Valve Diseases / Thrombotic events / Ventricular Outflow Obstruction1
3CompletedDiagnosticCoronary Artery Disease / Endothelial Function1
3CompletedHealth Services ResearchPharmacodynamics / Pharmacodynamics of Antiplatelet Agent1
3CompletedPreventionAcute Coronary Syndromes (ACS)2
3CompletedPreventionAtrial Fibrillation (AF) / Vascular Risk1
3CompletedPreventionAtrial Septal Aneurysm / Migraine / Patent Foramen Ovale (PFO) / Stroke, Ischemic1
3CompletedPreventionBrain Infarction / Systemic Embolism / Transient Ischaemic Attack (TIA)1
3CompletedPreventionHemodialysis Fistula Thrombosis / Renal Failure1
3CompletedPreventionMyocardial Infarction / Stable Angina (SA)1
3CompletedPreventionNSTEACS / Platelet Aggregation Inhibitors1
3CompletedPreventionPeripheral Arterial Disease (PAD)1
3CompletedPreventionPeripheral Artery Disease (PAD)1
3CompletedPreventionRenal Failure1
3CompletedPreventionStroke / Transient Ischaemic Attack (TIA)1
3CompletedTreatmentAcute Coronary Disease / Unstable Angina Pectoris1
3CompletedTreatmentAcute Coronary Syndromes (ACS)6
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Atherosclerosis / Percutaneous Coronary Intervention1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Coronary Arteriosclerosis1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Percutaneous Coronary Intervention1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Unstable Angina Pectoris1
3CompletedTreatmentAcute Ischemic Stroke (AIS)1
3CompletedTreatmentAcute Myocardial Infarction (AMI)1
3CompletedTreatmentArterial Occlusive Diseases1
3CompletedTreatmentArteriosclerosis1
3CompletedTreatmentAtrial Fibrillation (AF)1
3CompletedTreatmentAtrial Fibrillation (AF) / Percutaneous Coronary Intervention2
3CompletedTreatmentCarotid Artery Dissection / Cervical Artery Dissection / Stroke / Vertebral Artery Dissection1
3CompletedTreatmentCerebrovascular Accident / High Blood Pressure (Hypertension)1
3CompletedTreatmentChronic Kidney Disease (CKD)1
3CompletedTreatmentChronic Renal Failure (CRF) / Hemodialysis Treatment1
3CompletedTreatmentClopidogrel Non-Responsiveness1
3CompletedTreatmentCoronary Artery Bypass Graft Surgery Patients / Coronary Artery Disease1
3CompletedTreatmentCoronary Artery Disease10
3CompletedTreatmentCoronary Artery Disease / Diabetes Mellitus / Renal Insufficiency,Chronic1
3CompletedTreatmentCoronary Stent Implantation / Platelet Inhibition1
3CompletedTreatmentHeart Defects,Congenital2
3CompletedTreatmentHeart Failure1
3CompletedTreatmentMyocardial Infarction3
3CompletedTreatmentMyocardial Infarction / Myocardial Infarction (STEMI) <= 12 Hours / ST Elevation Myocardial Infarction (STEMI)1
3CompletedTreatmentMyocardial Infarction / ST Segment Elevation Myocardial Infarction (STEMI)1
3CompletedTreatmentPlatelet Reactivity1
3CompletedTreatmentST Segment Elevation Acute Myocardial Infarction / Thrombolysis in Myocardial Infarction Flow1
3CompletedTreatmentThrombotic events1
3Not Yet RecruitingPreventionStroke, Ischemic1
3Not Yet RecruitingTreatmentAcute Coronary Syndromes (ACS)1
3Not Yet RecruitingTreatmentAortic Valve Stenosis / Intracranial Embolism / Transcatheter Aortic Valve Replacement1
3Not Yet RecruitingTreatmentAtrial Fibrillation (AF)1
3Not Yet RecruitingTreatmentDiabetes Mellitus / Microvascular coronary artery disease1
3Not Yet RecruitingTreatmentIntracranial Atherosclerosis1
3RecruitingPreventionAcute Coronary Syndromes (ACS)1
3RecruitingPreventionAortic Valve Stenosis2
3RecruitingPreventionCerebral Hemorrhage1
3RecruitingPreventionCoronary Artery Disease1
3RecruitingTreatmentAcute Coronary Syndromes (ACS)2
3RecruitingTreatmentCardiovascular Heart Disease / Coronary Artery Disease / Myocardial Infarction / Myocardial Ischemia / Stent Thrombosis1
3RecruitingTreatmentCarotid Artery Occlusion / Middle Cerebral Artery Occlusion / Stroke1
3RecruitingTreatmentCarotid Stenosis1
3RecruitingTreatmentCerebral Aneurysms1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3RecruitingTreatmentChronic Kidney Disease (CKD) / Myocardial Infarction / Stroke, Ischemic1
3RecruitingTreatmentCritical Limb Ischemia (CLI)1
3RecruitingTreatmentPeripheral Arterial Disease, Antiplatelet Therapy1
3RecruitingTreatmentPeripheral Artery Disease (PAD)1
3RecruitingTreatmentStroke, Acute1
3TerminatedPreventionAtrial Fibrillation (AF) / Vascular Risk1
3TerminatedPreventionTranscatheter Aortic Valve Replacement1
3TerminatedTreatmentAcute Coronary Syndromes (ACS) / Atherosclerosis1
3TerminatedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease / Myocardial Infarction / Percutaneous Coronary Intervention1
3TerminatedTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction1
3TerminatedTreatmentAd Hoc Percutaneous Coronary Intervention / Chronic Stable Angina Pectoris1
3TerminatedTreatmentAdenocarcinoma of the Pancreas / Locally Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
3TerminatedTreatmentAngina Pectoris / Silent Ischemia1
3TerminatedTreatmentStroke1
3TerminatedTreatmentTransient Ischaemic Attack (TIA)1
3Unknown StatusBasic ScienceCardiovascular Heart Disease / Polyvascular Disease1
3Unknown StatusPreventionST Segment Elevation Acute Myocardial Infarction1
3Unknown StatusTreatmentAtherosclerosis1
3Unknown StatusTreatmentCoronary Artery Bypass Graft Surgery Patients / Graft Patency / Hypercoagulability / Thrombotic events1
3Unknown StatusTreatmentCoronary Artery Disease2
3Unknown StatusTreatmentCoronary Artery Stenosis / High Post-Treatment Platelet Reactivity / Late Platelet Aggregation / Maximal Platelet Aggregation1
3Unknown StatusTreatmentMajor Bleeding Outcomes / Platlet Aggregation1
3Unknown StatusTreatmentNon ST Segment Elevation Acute Coronary Syndrome1
3Unknown StatusTreatmentNon ST Segment Elevation Myocardial Infarction (NSTEMI) / Unstable Angina Pectoris1
3Unknown StatusTreatmentPercutaneous Coronary Intervention / Stable Angina (SA)1
3WithdrawnBasic ScienceCoronary Heart Disease (CHD)1
3WithdrawnTreatmentEndovascular Procedures / Peripheral Arterial Disease (PAD)1
4Active Not RecruitingPreventionAortic Valve Disorder / Bleeding / Myocardial Infarction / Stroke1
4Active Not RecruitingTreatmentAngina Pectoris1
4Active Not RecruitingTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentCoronary Heart Disease (CHD)1
4Active Not RecruitingTreatmentCoronary Heart Disease (CHD) / Percutaneous Transluminal Coronary Angioplasty1
4Active Not RecruitingTreatmentCoronary Microvascular Perfusion in Patients With Ischemic Heart Disease1
4Active Not RecruitingTreatmentNon ST Segment Elevation Acute Coronary Syndrome / Non-ST-Elevation Myocardial Infarction / Unstable Angina Pectoris1
4CompletedNot AvailableCoronary Heart Disease (CHD)1
4CompletedNot AvailableGastroduodenal Ulcers1
4CompletedNot AvailableHealthy Volunteers1
4CompletedBasic ScienceCoronary Artery Disease2
4CompletedBasic ScienceCoronary Artery Disease / Endothelial Dysfunction / Myocardial Ischemia1
4CompletedBasic ScienceDrug reactions1
4CompletedDiagnosticAcute Myocardial Infarction (AMI)1
4CompletedDiagnosticCoronary Artery Disease / Elective Percutaneous Coronary Intervention1
4CompletedDiagnosticCoronary Artery Stent Thrombosis1
4CompletedDiagnosticCoronary Heart Disease (CHD) / Percutaneous Coronary Intervention1
4CompletedHealth Services ResearchCoronary Artery Disease / Myocardial Infarction / Peripheral Vascular Disease Patient1
4CompletedHealth Services ResearchPeripheral Arterial Disease (PAD)1
4CompletedPreventionAortic Valve Disorder / Bleeding / Major Bleeding / Myocardial Infarction / Stroke1
4CompletedPreventionAortic Valve Disorder / Myocardial Infarction / Stroke1
4CompletedPreventionAspirin Resistance / Coronary Artery Disease1
4CompletedPreventionAtherosclerosis1
4CompletedPreventionCerebral Infarctions1
4CompletedPreventionCoronary Artery Disease3
4CompletedPreventionCoronary Artery Disease / Platelet Aggregation / Platelet Transcriptome1
4CompletedPreventionMigraine1
4CompletedPreventionNoncardioembolic Cerebral Infarction1
4CompletedPreventionStroke1
4CompletedPreventionStroke, Ischemic1
4CompletedScreeningHealthy Volunteers1
4CompletedSupportive CareCoronary Artery Disease1
4CompletedTreatmentAcute Coronary Syndromes (ACS)12
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Angina Pectoris / Cardiovascular Heart Disease / Heart Diseases / Myocardial Ischemia1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Clopidogrel Low Responsiveness / Percutaneous Coronary Intervention1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease / Percutaneous Coronary Intervention1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Ischemic Heart Disease1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Type 2 Diabetes Mellitus1
4CompletedTreatmentAcute Ischemic Stroke (AIS)1
4CompletedTreatmentAcute Myocardial Infarction (AMI)2
4CompletedTreatmentAneurysm coronary artery1
4CompletedTreatmentAngina Pectoris / Atherosclerosis / Coronary Heart Disease (CHD)1
4CompletedTreatmentAntiplatelet Therapy of Coronary Artery Bypass1
4CompletedTreatmentAortic Valve Stenosis / Stroke1
4CompletedTreatmentAtherosclerosis / Cerebral Infarctions1
4CompletedTreatmentBMI >27 kg/m2 / Cardiovascular Heart Disease1
4CompletedTreatmentBlood Pressures / Endothelial Function / Platelet Function1
4CompletedTreatmentCVD1
4CompletedTreatmentCardiac Arrest / Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction) / Postresuscitation Syndrome / ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction1
4CompletedTreatmentCardiovascular Heart Disease1
4CompletedTreatmentCarotid Stenosis1
4CompletedTreatmentCerebral Infarctions1
4CompletedTreatmentChronic Kidney Disease (CKD) / Stable Angina (SA)1
4CompletedTreatmentChronic Total Occlusion of Coronary Artery / Coronary Artery Disease / Coronary Artery Restenosis / Coronary Artery Stenosis / Coronary Heart Disease (CHD) / Myocardial Ischemia / Vascular Diseases1
4CompletedTreatmentComplete Occlusion of Coronary Artery / Hibernation, Myocardial1
4CompletedTreatmentCoronary Angioplasty / NSTEMI - Non-ST Segment Elevation MI / Type 2 Diabetes Mellitus1
4CompletedTreatmentCoronary Artery Disease24
4CompletedTreatmentCoronary Artery Disease / Diabetes Mellitus1
4CompletedTreatmentCoronary Artery Disease / Drug Interaction Potentiation / VA Drug Interactions [VA Drug Interaction]1
4CompletedTreatmentCoronary Artery Disease / Myocardial Ischemia / Stent Thrombosis1
4CompletedTreatmentCoronary Artery Disease / Percutaneous Coronary Intervention1
4CompletedTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus3
4CompletedTreatmentCoronary Heart Disease (CHD)3
4CompletedTreatmentCoronary Heart Disease (CHD) / Platelet Aggregation Inhibitors1
4CompletedTreatmentDiabetes Mellitus1
4CompletedTreatmentDiabetes Mellitus / Myocardial Infarction / Peripheral Arterial Disease (PAD)1
4CompletedTreatmentDrug Action Increased1
4CompletedTreatmentFibrinolysis / P2Y12 Inhibitor / ST Elevation Myocardial Infarction1
4CompletedTreatmentFractional Flow Reserve1
4CompletedTreatmentGastrointestinal Bleeding1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
4CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentInfluence of Aspirin on the Pharmacokinetics/Pharmacodynamics of Clopidogrel / Influence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of Clopidogrel1
4CompletedTreatmentIschaemia1
4CompletedTreatmentIschemic Heart Disease1
4CompletedTreatmentMetabolic Syndromes1
4CompletedTreatmentMyocardial Infarction2
4CompletedTreatmentNon ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Segment Elevation Myocardial Infarction (STEMI)1
4CompletedTreatmentNon-ST or ST Elevation Acute Coronary Syndromes1
4CompletedTreatmentPatients Who Are Scheduled to Undergo a PCI (Percutaneous Coronary Intervention) for CTO (Chronic Total Occlusion)1
4CompletedTreatmentPeripheral Arterial Disease (PAD)2
4CompletedTreatmentPlaque, Atherosclerotic1
4CompletedTreatmentPlatelet Reactivity1
4CompletedTreatmentPost procedural myocardial infarction1
4CompletedTreatmentSaphenous Vein Graft Atherosclerosis1
4CompletedTreatmentSevere Aortic Valve Stenosis / Transcatheter Aortic Valve Implantation / Transcatheter Aortic Valve Replacement1
4CompletedTreatmentStable Angina (SA)1
4CompletedTreatmentStable Coronary Artery Disease2
4CompletedTreatmentStroke1
4CompletedTreatmentThrombotic events1
4Enrolling by InvitationTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease / Stenosis1
4Enrolling by InvitationTreatmentCerebral Infarctions / CLOPIDOGREL, POOR METABOLISM of (Disorder)1
4Enrolling by InvitationTreatmentChronic Total Occlusion of Coronary Artery / Coronary Artery Disease / Percutaneous Coronary Intervention / Viable Myocardium1
4Not Yet RecruitingBasic ScienceArtery Occlusion / Aspirin Sensitivity / Cardiovascular Heart Disease / Clopidogrel, Poor Metabolism of / Coronary Artery Disease / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia / Platelet Thrombus / Platelets Dysfunction1
4Not Yet RecruitingHealth Services ResearchCoronary Artery Disease1
4Not Yet RecruitingPreventionMinor Stroke / Transient Ischaemic Attack (TIA)1
4Not Yet RecruitingTreatmentAcute Coronary Syndromes (ACS)2
4Not Yet RecruitingTreatmentAcute Coronary Syndromes (ACS) / Atrial Fibrillation (AF)1
4Not Yet RecruitingTreatmentAntiplatelet Therapy / Coronary Artery Disease / Percutaneous Coronary Intervention1
4Not Yet RecruitingTreatmentCoronary Artery Disease3
4Not Yet RecruitingTreatmentCoronary Artery Disease / Myocardial Infarction1
4Not Yet RecruitingTreatmentCoronary Heart Disease (CHD)1
4Not Yet RecruitingTreatmentEmbolic Stroke1
4Not Yet RecruitingTreatmentGlucose-6-Phosphate Dehydrogenase Deficiency / Stroke1
4Not Yet RecruitingTreatmentInflammatory Reaction / Thrombotic events1
4Not Yet RecruitingTreatmentLeft Atrial Appendage Closure / Non-valvular Atrial Fibrillation (NVAF)1
4Not Yet RecruitingTreatmentMigraine1
4RecruitingNot AvailableAcute Coronary Syndromes (ACS)1
4RecruitingBasic ScienceMyocardial Infarction1
4RecruitingBasic ScienceMyocardial Infarction / Platelets Dysfunction / Thrombotic events1
4RecruitingDiagnosticCoronary Artery Disease1
4RecruitingHealth Services ResearchPeripheral Artery Disease (PAD) / Stroke, Ischemic / Type 2 Diabetes Mellitus1
4RecruitingPreventionAcute Coronary Syndromes (ACS) / Chronic Kidney Disease (CKD)1
4RecruitingPreventionAtrial Fibrillation (AF)2
4RecruitingPreventionBleeding / Left Atrial Appendage Closure / Stroke / Thrombotic events / Transient Ischaemic Attack (TIA)1
4RecruitingTreatmentAcute Coronary Syndromes (ACS)2
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Cardiovascular Heart Disease / Coronary Arteriosclerosis / Myocardial Ischemia1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Chronic Kidney Disease (CKD) / End-Stage Renal Disease (ESRD)1
4RecruitingTreatmentAcute Myocardial Infarction (AMI)1
4RecruitingTreatmentAneurysm, Cerebral / Endovascular Procedures1
4RecruitingTreatmentAngina Pectoris / Cardiovascular Heart Disease / Chest Pain / Coronary Artery Disease / Heart Diseases / Infarction / Ischaemia / Myocardial Infarction / Systemic Embolism / Thrombotic events / Vascular Diseases1
4RecruitingTreatmentAntiplatelet Drugs / Stents / Unruptured Intracranial Aneurysm1
4RecruitingTreatmentAtherosclerosis / Coronary Artery Disease / Stents1
4RecruitingTreatmentAtrial Fibrillation (AF)1
4RecruitingTreatmentAtrial Fibrillation (AF) / Coronary Artery Disease1
4RecruitingTreatmentCardiovascular Mortality / Cerebrovascular Accident / Hemorrhage / Myocardial Infarction1
4RecruitingTreatmentChronic Kidney Disease (CKD) / Coronary Artery Disease / Type 2 Diabetes Mellitus1
4RecruitingTreatmentChronic Kidney Disease (CKD) / Non ST Segment Elevation Acute Coronary Syndrome1
4RecruitingTreatmentCoronary Artery Disease3
4RecruitingTreatmentCoronary Artery Disease / DES1
4RecruitingTreatmentCoronary Artery Disease / Diabetes Mellitus / Kidney Diseases / Myocardial Infarction1
4RecruitingTreatmentCoronary Artery Disease / Percutaneous Coronary Intervention1
4RecruitingTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus1
4RecruitingTreatmentCoronary Heart Disease (CHD)1
4RecruitingTreatmentCritical Limb Ischemia (CLI)1
4RecruitingTreatmentDrug-eluting Stent (DES) / Percutaneous Coronary Intervention1
4RecruitingTreatmentEndothelial Dysfunction / Vascular Inflammation1
4RecruitingTreatmentFemale Infertility1
4RecruitingTreatmentGastrointestinal Injury / Ischemic Heart Disease1
4RecruitingTreatmentIschemic Cerebrovascular Accident1
4RecruitingTreatmentMyocardial Fibrosis1
4RecruitingTreatmentMyocardial Infarction1
4RecruitingTreatmentNon ST Segment Elevation Myocardial Infarction (NSTEMI) / Stable Angina (SA) / Unstable Angina Pectoris1
4RecruitingTreatmentPeripheral Arterial Disease (PAD)1
4RecruitingTreatmentPlatelet Reactivity3
4RecruitingTreatmentProlonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage1
4RecruitingTreatmentST Elevation Myocardial Infarction / ST Segment Elevation Myocardial Infarction (STEMI)1
4RecruitingTreatmentStable Angina, Unstable Angina, Silent Coronary Ischemia, Coronary Artery Disease1
4RecruitingTreatmentStroke1
4TerminatedTreatmentAcute Coronary Syndromes (ACS) / Acute Myocardial Infarction (AMI) / Patients Who Are Hospitalized and Expected to Undergo PCI for Acute Coronary Syndrome, Including Acute Myocardial Infarction and Unstable Angina / Unstable Angina (Intermediate Coronary Syndrome)1
4TerminatedTreatmentAcute Coronary Syndromes (ACS) / Cardiovascular Heart Disease2
4TerminatedTreatmentAcute Myocardial Infarction (AMI)1
4TerminatedTreatmentAntiplatelet Therapy / Percutaneous Coronary Intervention / Stable Coronary Syndrome / Ticagrelor1
4TerminatedTreatmentAtrial Fibrillation (AF) / Coronary Artery Disease1
4TerminatedTreatmentBleeding / Coronary Artery Disease / Myocardial Ischemia1
4TerminatedTreatmentCoronary Artery Disease3
4TerminatedTreatmentCoronary Artery Disease / Thrombotic events1
4TerminatedTreatmentCoronary Graft Patency1
4TerminatedTreatmentNon ST Segment Elevation Acute Coronary Syndrome2
4Unknown StatusBasic ScienceAcute Coronary Syndromes (ACS) / Non ST Elevation Myocardial Infarction / ST Elevation Myocardial Infarction / Unstable Angina Pectoris1
4Unknown StatusBasic SciencePeripheral Arterial Disease (PAD)1
4Unknown StatusHealth Services ResearchAcute Coronary Syndromes (ACS) / ST Segment Elevation Acute Myocardial Infarction1
4Unknown StatusPreventionAcute Coronary Syndromes (ACS) / Myocardial Infarction1
4Unknown StatusPreventionAtherosclerosis / Cardiovascular Heart Disease1
4Unknown StatusPreventionCarotid Stenosis1
4Unknown StatusScreening30 Healthy People1
4Unknown StatusTreatmentAcute Coronary Syndromes (ACS)1
4Unknown StatusTreatmentAtrial Fibrillation (AF)1
4Unknown StatusTreatmentAtrial Fibrillation (AF) / Coronary Artery Disease1
4Unknown StatusTreatmentAtrial Fibrillation (AF) / Stroke1
4Unknown StatusTreatmentCoronary Artery Disease5
4Unknown StatusTreatmentCoronary Heart Disease (CHD)1
4Unknown StatusTreatmentCoronary Heart Disease (CHD) / Diabetes Mellitus1
4Unknown StatusTreatmentDiabetic Nephropathies / Type 2 Diabetes Mellitus / Vascular Diseases1
4Unknown StatusTreatmentEarly Gastric Cancer / Gastric Dysplasia1
4Unknown StatusTreatmentMyocardial Infarction1
4Unknown StatusTreatmentMyocardial Infarction / No-Reflow Phenomenon1
4Unknown StatusTreatmentPrimary Percutaneous Coronary Intervention / ST Elevation Myocardial Infarction (STEMI)1
4Unknown StatusTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
4WithdrawnNot AvailableAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
4WithdrawnBasic ScienceDiabetes1
4WithdrawnTreatmentAcute Myocardial Infarction (AMI)1
4WithdrawnTreatmentAnkle Brachial Index (0.9 or Less) / Arterial Occlusion Disease / Intermittent Claudication / Peripheral Artery Disease (PAD) / Vascular Diseases1
4WithdrawnTreatmentAtherosclerosis1
4WithdrawnTreatmentCoronary Artery Disease2
4WithdrawnTreatmentCoronary Heart Disease (CHD) / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Elevation Myocardial Infarction (STEMI) / Stable Angina (SA) / Unstable Angina Pectoris1
Not AvailableActive Not RecruitingTreatmentAcute Coronary Syndromes (ACS)2
Not AvailableActive Not RecruitingTreatmentStroke / Transient Ischaemic Attack (TIA)1
Not AvailableCompletedNot AvailableAcute Coronary Syndromes (ACS) / Bleeding / Clopidogrel / Novel Anti-platelets / Ticagrelor1
Not AvailableCompletedNot AvailableAcute Coronary Syndromes (ACS) / Coronary Arteriosclerosis1
Not AvailableCompletedNot AvailableAcute Coronary Syndromes (ACS) / Drug-eluting Stent (DES) / Percutaneous Coronary Intervention1
Not AvailableCompletedNot AvailableCoronary Artery Disease3
Not AvailableCompletedNot AvailableCoronary Heart Disease (CHD)1
Not AvailableCompletedNot AvailableCoronary Heart Disease (CHD) / Ischemic Heart Disease / Secondary Preventions / Stroke1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableHip Fracture1
Not AvailableCompletedNot AvailableIschemia, Brain / Ischemic Attack1
Not AvailableCompletedNot AvailableMyocardial Infarction1
Not AvailableCompletedNot AvailablePlatelet Aggregation Inhibitors1
Not AvailableCompletedNot AvailablePlatelets Dysfunction1
Not AvailableCompletedNot AvailableStable Angina (SA)1
Not AvailableCompletedBasic ScienceBlood Platelets / Clopidogrel1
Not AvailableCompletedBasic ScienceChest Pain / Coronary Artery Disease1
Not AvailableCompletedBasic ScienceEndotoxaemia1
Not AvailableCompletedDiagnosticCLOPIDOGREL, POOR METABOLISM of (Disorder) / Myocardial Ischemia1
Not AvailableCompletedDiagnosticCoronary Artery Disease1
Not AvailableCompletedDiagnosticPlatelet Dysfunction Due to Drugs / Risk Factor, Cardiovascular1
Not AvailableCompletedHealth Services ResearchDrug Drug Interaction (DDI)1
Not AvailableCompletedPreventionCardiovascular Heart Disease / Coronary Heart Disease (CHD) / Heart Diseases1
Not AvailableCompletedPreventionStroke1
Not AvailableCompletedPreventionVascular Surgery Patient With PAD / Carotid Stenosis1
Not AvailableCompletedTreatmentAcute Coronary Syndromes (ACS)3
Not AvailableCompletedTreatmentAngioplasty / Atherosclerosis1
Not AvailableCompletedTreatmentAnti Platelet Effects1
Not AvailableCompletedTreatmentCarotid Artery Stenosis1
Not AvailableCompletedTreatmentClopidogrel Non-Responsiveness1
Not AvailableCompletedTreatmentCoronary Artery Disease3
Not AvailableCompletedTreatmentCoronary Artery Disease / Drug Resistance1
Not AvailableCompletedTreatmentCoronary Heart Disease (CHD)1
Not AvailableCompletedTreatmentIschemic Heart Disease1
Not AvailableCompletedTreatmentMetabolism of Clopidogrel1
Not AvailableCompletedTreatmentMyocardial Infarction2
Not AvailableCompletedTreatmentPercutaneous Coronary Intervention1
Not AvailableEnrolling by InvitationPreventionCardiovascular Heart Disease1
Not AvailableEnrolling by InvitationTreatmentPeripheral Artery Disease (PAD)1
Not AvailableNot Yet RecruitingNot AvailableCoronary Artery Disease / Hyperuricemia1
Not AvailableNot Yet RecruitingNot AvailableCritical Limb Ischemia (CLI) / Intermittent Claudication / Peripheral Artery Disease (PAD)1
Not AvailableNot Yet RecruitingPreventionStroke, Acute / Transient Ischaemic Attack (TIA)1
Not AvailableNot Yet RecruitingTreatmentMigraine / Patent Foramen Ovale (PFO)1
Not AvailableNot Yet RecruitingTreatmentStroke1
Not AvailableRecruitingNot AvailableAcute Coronary Syndromes (ACS)1
Not AvailableRecruitingNot AvailableAcute Ischemic Stroke AIS / Intracranial Atherosclerosis ICAS1
Not AvailableRecruitingNot AvailableAcute Myocardial Infarction (AMI)1
Not AvailableRecruitingNot AvailableAngina Pectoris / Coronary Artery Disease1
Not AvailableRecruitingNot AvailableMCA - Middle Cerebral Artery Dissection1
Not AvailableRecruitingNot AvailablePlatelet Aggregation Onhibitors1
Not AvailableRecruitingNot AvailableStroke, Ischemic2
Not AvailableRecruitingPreventionAntiplatelet Effect / Stroke, Ischemic1
Not AvailableRecruitingPreventionComplication of Cardiac Defibrillator / Disorder of Cardiac Pacemaker System / Venous Occlusion1
Not AvailableTemporarily Not AvailableNot AvailableCoronary Artery Disease1
Not AvailableTerminatedNot AvailableStroke1
Not AvailableTerminatedDiagnosticAortic Valve Disorder1
Not AvailableUnknown StatusNot AvailableCarotid Artery Diseases1
Not AvailableUnknown StatusNot AvailableStroke, Ischemic1
Not AvailableUnknown StatusBasic ScienceHealthy Volunteers1
Not AvailableUnknown StatusTreatmentBlood Pressure Variability / Intracranial Artery Stenosis1
Not AvailableUnknown StatusTreatmentCoronary Artery Disease1
Not AvailableUnknown StatusTreatmentCoronary Artery Disease / PCI- Percutaneous Coronary Intervention / Platelet Aggregation Inhibitors1
Not AvailableUnknown StatusTreatmentDuodenal Ulcer / Gastric Ulcer1
Not AvailableUnknown StatusTreatmentHigh Cholesterol / Thrombotic events1
Not AvailableWithdrawnNot AvailableAcute Coronary Syndromes (ACS) / Non ST Elevation Myocardial Infarction / ST Elevation Myocardial Infarction / Unstable Angina Pectoris1
Not AvailableWithdrawnPreventionCarotid Artery Injury / Vertebral Artery Injury1

Pharmacoeconomics

Manufacturers
  • Dr reddys laboratories inc
  • Sanofi aventis us llc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • A-S Medication Solutions LLC
  • Bristol-Myers Squibb Co.
  • Cardinal Health
  • Comprehensive Consultant Services Inc.
  • Dept Health Central Pharmacy
  • Doctor Reddys Laboratories Ltd.
  • PD-Rx Pharmaceuticals Inc.
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Prepak Systems Inc.
  • Promex Medical Inc.
  • Remedy Repack
  • Sanofi-Aventis Inc.
  • Southwood Pharmaceuticals
  • Squibb Manufacturing Co.
  • Stat Rx Usa
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
TabletOral
TabletOral300 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral75 mg
TabletOral75 mg/1
KitOral
Tablet, film coatedOral300 mg
Tablet, film coatedOral
TabletOral300 mg
TabletOral75 mg
Tablet, film coatedOral75 mg/1
Prices
Unit descriptionCostUnit
Plavix 300 mg tablet24.86USD tablet
Plavix 75 mg tablet9.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4847265No1989-07-112011-11-17Us
CA2334870No2005-03-152019-06-10Canada
CA1336777No1995-08-222012-08-22Canada
US6429210Yes2002-08-062019-12-10Us
US6504030Yes2003-01-072019-12-10Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)158 °Chttp://www.chemspider.com/Chemical-Structure.54632.html?rid=9b9b483b-9db2-454c-a1be-2494307b6b23&page_num=0
Predicted Properties
PropertyValueSource
Water Solubility0.0118 mg/mLALOGPS
logP3.84ALOGPS
logP4.03ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)5.14ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity84.93 m3·mol-1ChemAxon
Polarizability33.19 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9847
Caco-2 permeable+0.5777
P-glycoprotein substrateSubstrate0.6664
P-glycoprotein inhibitor IInhibitor0.6556
P-glycoprotein inhibitor IIInhibitor0.5558
Renal organic cation transporterInhibitor0.6368
CYP450 2C9 substrateNon-substrate0.7407
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6339
CYP450 1A2 substrateInhibitor0.724
CYP450 2C9 inhibitorNon-inhibitor0.5223
CYP450 2D6 inhibitorInhibitor0.5712
CYP450 2C19 inhibitorInhibitor0.8071
CYP450 3A4 inhibitorNon-inhibitor0.7389
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9188
Ames testNon AMES toxic0.7112
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.9911
Rat acute toxicity2.4887 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7548
hERG inhibition (predictor II)Non-inhibitor0.6329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (71.9 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0229-0967000000-6c51c479e90818ec703b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-2900000000-be6dbedd4a0c4f60d0dd

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid esters
Alternative Parents
Thienopyridines / Aralkylamines / Chlorobenzenes / Aryl chlorides / Pyridines and derivatives / Methyl esters / Heteroaromatic compounds / Thiophenes / Trialkylamines / Monocarboxylic acids and derivatives
show 6 more
Substituents
Alpha-amino acid ester / Thienopyridine / Chlorobenzene / Halobenzene / Aralkylamine / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Pyridine / Benzenoid
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
methyl ester, monochlorobenzenes, thienopyridine (CHEBI:37941)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name
P2RY12
Uniprot ID
Q9H244
Uniprot Name
P2Y purinoceptor 12
Molecular Weight
39438.355 Da
References
  1. Dorsam RT, Murugappan S, Ding Z, Kunapuli SP: Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. Hematology. 2003 Dec;8(6):359-65. [PubMed:14668029]
  2. Herbert JM, Savi P: P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. [PubMed:15199474]
  3. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schomig A, Schomig E: Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004 Aug;92(2):311-6. [PubMed:15269827]
  4. Wang L, Jacobsen SE, Bengtsson A, Erlinge D: P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol. 2004 Aug 3;5:16. [PubMed:15291969]
  5. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D: ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1810-5. Epub 2004 Aug 12. [PubMed:15308557]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML: The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008 Dec;1(6):620-7. doi: 10.1016/j.jcin.2008.09.008. [PubMed:19463375]
  8. Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P, Herbert JM: The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11069-74. Epub 2006 Jul 11. [PubMed:16835302]
  9. van Gestel MA, Heemskerk JW, Slaaf DW, Heijnen VV, Reneman RS, oude Egbrink MG: In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):518-23. Epub 2003 Jan 23. [PubMed:12615691]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ: Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003 Aug 26;108(8):921-4. Epub 2003 Aug 18. [PubMed:12925453]
  3. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A: Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. Eur Heart J. 2003 Oct;24(19):1744-9. [PubMed:14522569]
  4. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004 Jan 20;109(2):166-71. Epub 2004 Jan 5. [PubMed:14707025]
  5. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA: Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart. 2005 Jan;91(1):23-6. [PubMed:15604326]
  6. Poulsen TS, Vinholt P, Mickley H, Korsholm L, Kristensen SR, Damkier P: Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence. Basic Clin Pharmacol Toxicol. 2005 Feb;96(2):103-10. [PubMed:15679472]
  7. Clarke TA, Waskell LA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003 Jan;31(1):53-9. [PubMed:12485953]
Details
2. Cytochrome P450 2B6
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger UM: Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther. 2004 Jan;308(1):189-97. doi: 10.1124/jpet.103.056127. Epub 2003 Oct 16. [PubMed:14563790]
  2. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K: Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005 Jun;77(6):553-9. doi: 10.1016/j.clpt.2005.02.010. [PubMed:15961986]
  3. Sangkuhl K, Klein TE, Altman RB: Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5. doi: 10.1097/FPC.0b013e3283385420. [PubMed:20440227]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Turgeon J, Pharand C, Michaud V: Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism. CMAJ. 2006 Jun 6;174(12):1729. doi: 10.1503/cmaj.060502. [PubMed:16754901]
  2. Clarke TA, Waskell LA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003 Jan;31(1):53-9. [PubMed:12485953]
Details
4. Cytochrome P450 2C19
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Ford NF: The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway. J Clin Pharmacol. 2016 Dec;56(12):1474-1483. doi: 10.1002/jcph.769. Epub 2016 Jun 22. [PubMed:27196064]
  2. Chen K, Zhang R, Liu H, Guo X, Li P, Liu X: Impact of the CYP2C19 Gene Polymorphism on Clopidogrel Personalized Drug Regimen and the Clinical Outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780. doi: 10.7754/Clin.Lab.2016.160216. [PubMed:28164572]
  3. Flockhart Table of Drug Interactions [Link]
  4. Clopidogrel Therapy and CYP2C19 Genotype [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Curator comments
Clopidogrel inhibited CYP2C9 at high concentrations in vitro, but showed no effects on the pharmacokinetics of warfarin (CYP2C9 substrate) when clopidogrel was administered at 75 mg a day [F1912].
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger UM: Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther. 2004 Jan;308(1):189-97. doi: 10.1124/jpet.103.056127. Epub 2003 Oct 16. [PubMed:14563790]
  2. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE: Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41. doi: 10.1038/sj.clpt.6100139. Epub 2007 Mar 14. [PubMed:17361128]
  3. Clopidogrel FDA label [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Sangkuhl K, Klein TE, Altman RB: Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5. doi: 10.1097/FPC.0b013e3283385420. [PubMed:20440227]
  2. Jiang XL, Samant S, Lesko LJ, Schmidt S: Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147-66. doi: 10.1007/s40262-014-0230-6. [PubMed:25559342]
  3. Polasek TM, Doogue MP, Miners JO: Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Ther Adv Drug Saf. 2011 Dec;2(6):253-61. doi: 10.1177/2042098611422559. [PubMed:25083217]
  4. Clopidogrel FDA label [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Itkonen MK, Tornio A, Filppula AM, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT: Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans. Clin Pharmacol Ther. 2018 Sep;104(3):495-504. doi: 10.1002/cpt.947. Epub 2017 Dec 23. [PubMed:29171020]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS: Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013 Mar;344(3):665-72. doi: 10.1124/jpet.112.201640. Epub 2012 Dec 28. [PubMed:23275066]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schomig A, Schomig E: Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501. [PubMed:17112805]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Li L, Song F, Tu M, Wang K, Zhao L, Wu X, Zhou H, Xia Z, Jiang H: In vitro interaction of clopidogrel and its hydrolysate with OCT1, OCT2 and OAT1. Int J Pharm. 2014 Apr 25;465(1-2):5-10. doi: 10.1016/j.ijpharm.2014.02.003. Epub 2014 Feb 11. [PubMed:24530383]
  2. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER: Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes. 2015 May;64(5):1786-93. doi: 10.2337/db14-1388. Epub 2014 Dec 15. [PubMed:25510240]
  3. Stage TB, Brosen K, Christensen MM: A Comprehensive Review of Drug-Drug Interactions with Metformin. Clin Pharmacokinet. 2015 Aug;54(8):811-24. doi: 10.1007/s40262-015-0270-6. [PubMed:25943187]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Li L, Song F, Tu M, Wang K, Zhao L, Wu X, Zhou H, Xia Z, Jiang H: In vitro interaction of clopidogrel and its hydrolysate with OCT1, OCT2 and OAT1. Int J Pharm. 2014 Apr 25;465(1-2):5-10. doi: 10.1016/j.ijpharm.2014.02.003. Epub 2014 Feb 11. [PubMed:24530383]

Drug created on June 13, 2005 07:24 / Updated on January 19, 2020 23:38